stockrow
Saturday 7 November 2026
Export ANVS’s income statement to Excel — free account
Annovis Bio, Inc.
ANVS Healthcare Biotechnology
- EPS
- −25.0%
- Free cash flow
- −329.2%
Quarter to June 2026, against a year earlier
0.82
0.15
+22.39%
Follow ANVS
Alert me
Annovis Bio, Inc. (ANVS) P/E ratio
Annovis Bio, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| IRLA IRulya Therapeutics Inc. compare | n/m |
| ACET Adicet Bio, Inc. compare | n/m |
| ANVS Annovis Bio, Inc. | n/m |
| ALGS Aligos Therapeutics, Inc. compare | n/m |
| BCTX BRIACELL THERAP compare | n/m |
| MGX Metagenomi Therapeutics, Inc. compare | n/m |
| LITS Lite Strategy, Inc. compare | n/m |
| EDSA Edesa Biotech, Inc. compare | n/m |
| PLRZ Polyrizon Ltd. compare | — |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)